Over 1,100 police encounters in UP under Yogi govt a very serious issue: Supreme Court

Agencies
January 15, 2019

New Delhi, Jan 15: The Supreme Court on Monday observed that a “very serious issue” has been raised in a petition seeking a CBI probe into 1,100 police encounters which have taken place in Uttar Pradesh under the Yogi Adityanath government.

The petition said the encounters killed 49 people and injured 370.

Filed by the NGO, People’s Union of Civil Liberties (PUCL), the petition termed the encounters “massive administrative liquidations”.

On Monday, a Bench led by Chief Justice of India Ranjan Gogoi adjourned the case to February 12.

‘Endorsed by the State’

The court had asked the State government to first file its response to the petition way back on July 2 last year.

The PUCL has submitted that the police encounters were endorsed by the State administration in “open defiance” of human rights and civil liberties. That is, the State machinery chose to end lives instead of bringing people for trial.

Comments

ayes p.
 - 
Tuesday, 15 Jan 2019

as per these jungle raj administration they do not want any more courts just they want to encounter.

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 30,2020

Hyderabad, Jun 30: Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

The Drug Controller General of India - CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020.

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech.

The indigenous, inactivated vaccine developed and manufactured in the company's Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad.

Announcing the vaccine development milestone, Dr Krishna Ella, Chairman and Managing Director said: "We are proud to announce COVAXIN, India's first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine."

Dr Ella added, "The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform."
Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses.

Speaking about Bharat Biotech's prowess, Suchitra Ella, Joint Managing Director said, "Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic."
"Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India's strength in handling future pandemics," she added.

Bharat Biotech's track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 28,2020

New Delhi, Apr 28: Nafisa Ali took to Instagram to share the inspiring story of her niece, Diya Naidu, who donated her plasma to help patients suffering from Covid-19 after recovering from the disease. The veteran actress shared a photo of her niece from the hospital bed and asked fans to read Diya's post to get a detailed account of her experience.

Nafisa wrote, "Diya Naidu my niece - a COVID19 hero - is back home after donating her plasma - looks like liquid gold - it’s value is priceless as it will save lives. So please read her COVID19 story and share the information that is first hand. It is the need of the hour. Help save lives. #diyanise. #diyanaidu #covid_19 #india (sic)."

Diya Naidu, who is a dancer and choreographer based in Bengaluru, revealed in her Instagram post that she has donated her plasma for other Covid-19 patients. She said that the method has been super effective wherever it's been tried.

Earlier, Nafisa Ali gave a shout-out to her niece on Instagram and penned a heartfelt note for her. She wrote, "I am so grateful to you brave child - a COVID19 warrior (living in Bangalore) has agreed to donate her plasma to help cure other COVID19 serious patients (sic)."

Explaining the process of plasma therapy to treat Covid-19 patients, she wrote, "The process of donating plasma to treat COVID-19 is not very complex and can be done in just two hours. One of the most discussed methods of treatment of the disease caused by the novel coronavirus is plasma therapy, which involves the transfusion of plasma from a convalescent coronavirus patient to a critical patient. The blood of a recovering patient is rich in antibodies produced by the body to fight the virus, which are expected to help the critical patient recover (sic)."

Plasma therapy has been suggested to treat people suffering from Covid-19. People, who have recovered from the disease, are donating plasma as it contains antibodies to fight the disease. Earlier, Kanika Kapoor, who was the first Bollywood celebrity to be diagnosed with the disease, also offered to donate her plasma. She has recovered from Covid-19 and is currently living with her family in Lucknow.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 12,2020

New Delhi, May 12: With 3,604 more COVID-19 cases reported in the last 24 hours, India's tally of coronavirus cases reached 70,756, said the Union Ministry of Health and Family Welfare on Tuesday. 87 deaths were reported during the period.

As per the tally, 46,008 patients are active coronavirus cases while 22,454 patients have been cured/discharged and one patient has migrated.

With 87 deaths due to COVID-19 reported in the last 24 hours, the number of deaths has risen to 2,293.

As per the ministry, Maharashtra has the most number of coronavirus cases with 23,401 cases with 4,786 patients being cured/discharged while 868 deaths have been reported in the state.

Gujarat is second on the list with 8,541 cases that include 2,780 patients recovering from the disease and 513 fatalities.

Tamil Nadu's tally reached 8,002 cases, including 2,051 recoveries and 53 deaths.

While Delhi's tally stands at 7,233 cases with 2,129 patients recovered and 73 deaths.

Meanwhile; Mizoram (one case reported--now recovered), Goa (seven cases reported and all seven recovered), Manipur (Two cases reported and both patients recovered) and Arunachal Pradesh (one case reported--now recovered) have reported no new cases in the last 24 hours.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.